HASBROUCK HEIGHTS, N.J., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company will hold a conference call at 8:30 a.m. Friday, December 17, 2010 to discuss the recently announced European licensing agreement with Recordati for the development and commercialization of NX-1207. The Company invites anyone wishing to participate in the conference call to dial 1-866-696-5910 (toll free) and enter the pass code 8727761. You should dial in five minutes prior to the 8:30 a.m. scheduled start of the teleconference in order to ensure participation. More information about Nymox is available at www.nymox.com; email: email@example.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Nymox Pharmaceutical Corporation Roy Wolvin 1-800-93NYMOX www.nymox.com